IFRX

#3701
InflaRx N.V. - Common Stock
2.2 9 USD
+0.06%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
2.29
2.29
Intervallo Annuale
0.80
2.94
Variazione giornaliera
+6.02%
Variazione Mensile
+28.65%
Variazione di 6 mesi
+151.65%
Variazione Annuale
+36.31%
Chiusura Precedente
2.1 6
Open
2.2 9
Minimo
2.2 9
Massimo
2.2 9
Volume
23
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Inflarx N.V. current report, Q3 FY2026
6-K
Current report, Q2 FY2026
Inflarx N.V. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
Inflarx N.V. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
Inflarx N.V. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
Inflarx N.V. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
Inflarx N.V. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
Inflarx N.V. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
Inflarx N.V. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
Inflarx N.V. current report, Q2 FY2026
6-K
Current report, Q1 FY2026
Inflarx N.V. current report, Q1 FY2026
6-K

Inflarx N.V. current report, Q4 FY2021

Full document

InflaRx N.V. Form 6-K Summary

Business Context and Reporting Period

This Form 6-K was filed by InflaRx N.V., a foreign private issuer based in Jena, Germany, on November 5, 2021. The filing incorporates by reference the company's Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis (MD&A) for the three and nine months ended September 30, 2021 (Exhibits 99.1 and 99.2), as well as a press release dated November 5, 2021 (Exhibit 99.3).

Key Financial Metrics

The provided text contains only the cover page, signature block, and exhibit index of the Form 6-K. It does not include the actual financial data from the incorporated exhibits. Therefore, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text. The filing text does not provide a clear value for any financial metric.

Material Changes

No material changes versus prior periods can be identified from the provided text as the comparative financial data is located in the incorporated exhibits (99.1 and 99.2) which are not included in the input content.

Guidance, Outlook, and Risks

The filing references a press release (Exhibit 99.3) which typically contains management commentary, outlook, and risk factors, but the content of this press release is not included in the provided text. Consequently, no specific guidance, risks, contingencies, or unusual items can be summarized from the available information.

Investor Verification Checklist

  • Review Exhibit 99.1 for the actual Unaudited Condensed Consolidated Financial Statements to verify cash burn rate and liquidity position.
  • Examine Exhibit 99.2 (MD&A) for management's explanation of operational results and material changes for the nine months ended September 30, 2021.
  • Read Exhibit 99.3 (Press Release) for specific updates on clinical trial progress, regulatory milestones, or strategic partnerships announced on November 5, 2021.
  • Confirm the status of the registration statements (Form S-8 and Form F-3) referenced in the incorporation by reference section.

Notizie